Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ruxolitinib in Patients with MPNs and Elevated Blasts

Leuk Lymphoma; 2017 Apr; Naqvi, Daver, et al

Publish date:: February 12, 2017

Ruxolitinib was safely combined with hypomethylating agents in patients with myeloproliferative neoplasms and elevated blasts, according to a review involving 45 individuals.

Patients had myelofibrosis (n=35) or other neoplasms (n=10) treated off study at a single center. They had advanced features and were refractory to multiple therapies. Among the results:

Ruxolitinib was able to reduce splenomegaly (51% response rate) and constitutional symptoms (42% response rate).
It controlled blood counts in patients with polycythemia and thrombocythemia.
It was not effective in patients with non-classic MPNs.

Citation:

Naqvi K, Daver N, Pemmaraju N, et al. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma. 2017;58(4):866-871. doi:10.1080/10428194.2016.1217528.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Hematologic Malignancies

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al

These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al

Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al

The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al